VEGFA and age-related macular degeneration: Additionally, brolucizumab showed a robust anatomical response in cases resistant to other anti-VEGF treatments, such as ranibizumab and aflibercept, indicating the potential of brolucizumab as an effective alternative treatment for refractory AMD [5,6].